Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Automation in coagulation was the topic of a Nov. 11, 2024 roundtable led by CAP TODAY publisher Bob McGonnagle. Put it on a line or on a dedicated automation platform? Seven participants talked about that and about cybersecurity, viscoelastic testing, and the labor shortage, among other things.
December 2024—There is no disguising the enthusiasm—not to mention expertise—that David Miklos, MD, PhD, brings to the topic of chimeric antigen receptor T-cell therapies. CAR T-cell products have been strikingly effective in treating large B-cell lymphoma and multiple myeloma, as well as other hematologic malignancies such as acute lymphoblastic leukemia, follicular lymphoma, and mantle cell lymphoma. Sounding equal parts life coach and physician, Dr. Miklos sees nearly limitless potential in this immunotherapy, which entails genetically engineering T cells to express engineered molecules that can recognize and bind to specific antigens on cancer cells. “So much is possible,” he says. “Our little minds are limiting this, not the potential of science. There are a lot of obvious and mind-blowingly effective strategies that are just coming home to roost. We have really blown open the opportunity to advance therapies more quickly, to apply multipronged approaches using logic loops that are essentially programmed into a cell. It’s really exciting.”
December 2024—On the heels of the publication of a joint consensus recommendation on DPYD genotyping, setting out what variants to test for, two experts who have studied the use of DPYD genotyping shed light in CAP TODAY interviews on its importance and its real-world impact.
December 2024—The new edition of the CAP accreditation program checklists will contain revised requirements for the qualification of laboratory directors, technical and general supervisors, technical and clinical consultants, and moderate- and high-complexity testing personnel.
December 2024—Digital pathology in 2024—what’s the sentiment, the pace, the holdup, the worry? Five people spoke online with CAP TODAY publisher Bob McGonnagle on Oct. 9 about the state of play as the end of the year neared.
December 2024—Payment policies that the CAP championed to protect the value of pathology services have been captured in the 2025 Medicare physician fee schedule published on Nov. 1. The Centers for Medicare and Medicaid Services included in the 2025 fee schedule updated relative value units for three apheresis services and increased nonphysician cost components for key pathology and laboratory labor types. In a separate hospital payment regulation for 2025, the CMS also declined to move forward with surgical pathology tissue exam payment decreases to which the CAP objected.
December 2024—A National Cancer Institute trial known as MyeloMATCH, rolling out now, aims to improve the acute myeloid leukemia survival rate and relies on 72-hour turnaround times for cytogenetics, FISH, flow cytometry, and next-generation sequencing. In MyeloMATCH (Molecular Analysis for Therapy Choice), researchers are hoping to find new treatments for AML and myelodysplastic syndrome by rapidly matching patients with a trial that tests a treatment designed to target the mutations detected in the patient blood and bone marrow samples.
December 2024—Some health systems have sold their clinical laboratory outreach business; others seek to grow theirs. CAP TODAY publisher Bob McGonnagle asked Compass Group members for a quick look at their outreach programs when they met online on Nov. 5. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.
December 2024—Case. A 73-year-old male with a clinical history of benign prostatic hypertrophy and pituitary macroadenoma status post-resection presented with lymphocytosis. This incidental lymphocytosis was noted within a preoperative CBC for a prostate procedure. At the time he was asymptomatic; medications included hydrocortisone, testosterone, and levothyroxine. Lymphadenopathy and splenomegaly were absent on physical examination. Complete blood counts showed WBC 25.8 × 109/L, hemoglobin 13.9 g/dL, hematocrit 42 percent, and platelets 134 × 109/L.
November 2024—David Grenache, PhD, D(ABCC), chief scientific officer of TriCore, is breaking no new ground when he considers the maternal serum alpha-fetoprotein test and says, “A screening test is designed to put people into one of two camps.” No scientific advances there. But the reverberations of this particular screening test have landed patients and physicians in complicated situations of late. The obvious divide is to identify increased risk of fetal abnormalities, including open neural tube defects. But the test has historically incorporated a race adjustment for Black patients. And that adjustment—seen as a way to account for reported differences in AFP values between Black and non-Black pregnant persons—in turn has come under more scrutiny recently as physicians question whether the adjustment should continue to be used, or whether it should be dropped, à la the race adjustment for eGFR/renal function. Compared with eGFR, evaluating the race adjustment in maternal serum AFP screening is more in its infancy, Dr. Grenache says.
